TY - JOUR
T1 - Social influences on clinical outcomes of patients with ovarian cancer
AU - Lutgendorf, Susan K.
AU - De Geest, Koen
AU - Bender, David
AU - Ahmed, Amina
AU - Goodheart, Michael J.
AU - Dahmoush, Laila
AU - Zimmerman, M. Bridget
AU - Penedo, Frank J.
AU - Lucci, Joseph A.
AU - Ganjei-Azar, Parvin
AU - Thaker, Premal H.
AU - Mendez, Luis
AU - Lubaroff, David M.
AU - Slavich, George M.
AU - Cole, Steven W.
AU - Sood, Anil K.
PY - 2012
Y1 - 2012
N2 - Purpose: Previous research has demonstrated relationships of social support with disease-related biomarkers in patients with ovarian cancer. However, the clinical relevance of these findings to patient outcomes has not been established. This prospective study examined how social support relates to long-term survival among consecutive patients with ovarian cancer. We focused on two types of social support: social attachment, a type of emotional social support reflecting connections with others, and instrumental social support reflecting the availability of tangible assistance. Patients and Methods: Patients were prospectively recruited during a presurgical clinic visit and completed surveys before surgery. One hundred sixty-eight patients with histologically confirmed epithelial ovarian cancer were observed from the date of surgery until death or December 2010. Clinical information was obtained from medical records. Results: In a Cox regression model, adjusting for disease stage, grade, histology, residual disease, and age, greater social attachment was associated with a lower likelihood of death (hazard ratio [HR], 0.87; 95% CI, 0.77 to 0.98; P = .018). The median survival time for patients with low social attachment categorized on a median split of 15 was 3.35 years (95% CI, 2.56 to 4.15 years). In contrast, by study completion, 59% of patients with high social attachment were still alive after 4.70 years. No significant association was found between instrumental social support and survival, even after adjustment for covariates. Conclusion: Social attachment is associated with a survival advantage for patients with ovarian cancer. Clinical implications include the importance of screening for deficits in the social environment and consideration of support activities during adjuvant treatment.
AB - Purpose: Previous research has demonstrated relationships of social support with disease-related biomarkers in patients with ovarian cancer. However, the clinical relevance of these findings to patient outcomes has not been established. This prospective study examined how social support relates to long-term survival among consecutive patients with ovarian cancer. We focused on two types of social support: social attachment, a type of emotional social support reflecting connections with others, and instrumental social support reflecting the availability of tangible assistance. Patients and Methods: Patients were prospectively recruited during a presurgical clinic visit and completed surveys before surgery. One hundred sixty-eight patients with histologically confirmed epithelial ovarian cancer were observed from the date of surgery until death or December 2010. Clinical information was obtained from medical records. Results: In a Cox regression model, adjusting for disease stage, grade, histology, residual disease, and age, greater social attachment was associated with a lower likelihood of death (hazard ratio [HR], 0.87; 95% CI, 0.77 to 0.98; P = .018). The median survival time for patients with low social attachment categorized on a median split of 15 was 3.35 years (95% CI, 2.56 to 4.15 years). In contrast, by study completion, 59% of patients with high social attachment were still alive after 4.70 years. No significant association was found between instrumental social support and survival, even after adjustment for covariates. Conclusion: Social attachment is associated with a survival advantage for patients with ovarian cancer. Clinical implications include the importance of screening for deficits in the social environment and consideration of support activities during adjuvant treatment.
UR - http://www.scopus.com/inward/record.url?scp=84865073284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865073284&partnerID=8YFLogxK
U2 - 10.1200/JCO.2011.39.4411
DO - 10.1200/JCO.2011.39.4411
M3 - Article
C2 - 22802321
AN - SCOPUS:84865073284
SN - 0732-183X
VL - 30
SP - 2885
EP - 2890
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 23
ER -